Time-dependent inhibition (TDI) of CYP1A2 by a CYP3A4-mediated reactive metabolite: proposal for a novel mechanism of irreversible TDI by a non-suicide substrate

References

• Argoti D, Liang L, Conteh A, et al. (2005). Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol 18:1537–44.
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. (2014). Current IUBMB recommendations on enzyme nomenclature and kinetics. Perspect Sci 1:74–87.
   Google Scholar
• Fairman DA, Collins C, Chapple S. (2007). Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos 35:2159–65.
   PubMed Web of Science ®Google Scholar
• Gan J, Harper TW, Hsueh MM, et al. (2005). Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites. Chem Res Toxicol 18:896–903.
   PubMed Web of Science ®Google Scholar
• Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189–205.
   PubMed Web of Science ®Google Scholar
• Jian W, Liu HF, Zhao W, et al. (2012). Simultaneous screening of glutathione and cyanide adducts using precursor ion and neutral loss scans-dependent product ion spectral acquisition and data mining tools. J Am Soc Mass Spectrom 23:964–76.
   PubMed Web of Science ®Google Scholar
• Kamel A, Harriman S. (2013). Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov Today Technol 10:e177–89.
   PubMedGoogle Scholar
• Kato T, Matsumoto Y, Yamamoto M, et al. (2015). DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect 3:e00142.
   PubMed Web of Science ®Google Scholar
• Kenny JR, Mukadam S, Zhang C, et al. (2012). Drug–drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 29:1960–76.
   PubMed Web of Science ®Google Scholar
• Köhler GI, Bode-Böger SM, Busse R, et al. (2000). Drug–drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504–13.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Trager WF. (1993). Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649–56.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee SY, Oh SJ, et al. (2012). Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chem Biol Interact 198:49–56.
   PubMed Web of Science ®Google Scholar
• Lewis DF. (2003). Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 10:1955–72.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361–90.
   PubMed Web of Science ®Google Scholar
• Masumoto H, Ohta S, Hirobe M. (1991). Application of chemical cytochrome P-450 model systems to studies on drug metabolism. IV. Mechanism of piperidine metabolism pathways via an iminium intermediate. Drug Metab Dispos 19:768–80.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–55.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191–7.
   PubMed Web of Science ®Google Scholar
• Orr ST, Ripp SL, Ballard TE, et al. (2012). Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55:4896–933.
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6.
   PubMed Web of Science ®Google Scholar
• Pelkonen O. (2002). Human CYPs: in vivo and clinical aspects. Drug Metab Rev 34:37–46.
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51–66.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Higashida A, Kato M, et al. (2009). Prediction of drug–drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 24:500–10.
   PubMed Web of Science ®Google Scholar
• Tarrus E, Cami J, Roberts DJ, et al. (1987). Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9–18.
   PubMed Web of Science ®Google Scholar
• Taxak N, Desai PV, Patel B, et al. (2012). Metabolic-intermediate complex formation with cytochrome P450: theoretical studies in elucidating the reaction pathway for the generation of reactive nitroso intermediate. J Comput Chem 33:1740–7.
   PubMed Web of Science ®Google Scholar
• Yan Z, Maher N, Torres R, et al. (2007). Use of a trapping agent for simultaneous capturing and high-throughput screening of both “soft” and “hard” reactive metabolites. Anal Chem 79:4206–14.
   PubMed Web of Science ®Google Scholar
• Yoshinaga H, Nishida T, Sasaki I, et al. (2018). Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity. Bioorg Med Chem 26:1614–27.
   PubMed Web of Science ®Google Scholar
• Zhou ZW, Zhou SF. (2009). Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol 5:579–605.
   PubMed Web of Science ®Google Scholar